MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.

Slides:



Advertisements
Similar presentations
DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Advertisements

Improving diagnosis TB laboratory strengthening.
TB and HIV: Tightly Linked… and Why We Should Care.
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
Scaling up Prevention of Mother to Child Transmission of HIV (PMTCT): What Will it Take to Eliminate MTCT? Jessica Rodrigues Presentation for UNICEF Written.
Accelerating PMDT scale up in Ethiopia
Measuring Mosquito Mortality Christen Fornadel, PhD Global Health Mini-University 3/7/14.
Country Progress Report Philippines
Technical Advisory Group meeting, WHO/WPRO
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
experience from Lesotho
Thank you for viewing this presentation.
The Global Plan to Stop TB, (1)
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
EQUI - TB Knowledge Programme Quality Assured TB Care for Poor People in Resource Constrained settings 2001 – 2006 Purpose: To promote implementation of.
How are Malaria in Pregnancy (MIP) Programs Measuring Up? Aimee Dickerson and Mary Drake USAID Mini-University March 7, 2014.
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
What Can We Do When Markets Fall Short? Mini-U Session, March 2014.
Combat HIV-AIDS, malaria & other diseases Goal 6..
Mongolia Progress Report Dr. D. Otgontsetseg, Head of recording and reporting unit, TB surveillance and research department, NCCD The ninth Technical Advisory.
COUNTRY ACTION: SUSTAINABLE INVESTMENT STOP TB PARTNERSHIP FORUM STOP TB PARTNERSHIP FORUM 24TH-26TH MARCH TH-26TH MARCH 2004 BY BY MRS NENADI USMAN.
Prevention and improved treatment of communicable diseases (HIV/AIDS and TB), including increasing preparedness for bioterrorism and epidemics Anneli Taal,
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting Cheryl McDermid, Helen Cox, Simiso Sokhela, Gilles van Cutsem,
Three key messages on tuberculosis control World Tuberculosis Day 2010 ECDC TB Team European Centre for Disease Prevention and Control Stockholm, 24 March.
Monitoring and Evaluation Module 12 – March 2010.
Tuberculosis Research of INA-RESPOND on Drug-resistant
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Models of Care for Paediatric HIV Miriam Chipimo MD MPH Reproductive Health & HIV&AIDS Manager, UNICEF, Malawi.
World TB Day 2000 Forging New Partnerships to Stop TB Produced by the [ Stop TB Initiative ] Coordinating Team: WHO.
Progress of the Singapore TB Elimination Programme (STEP)
Session 11: MDR & XDR-TB: How Can Business Help Stem the Tide?
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
1 Oct 2005 WHO/STB/THD World Health Organization 4 th Meeting of Subgroup on laboratory capacity strengthening Paris, France, October Ernesto Jaramillo.
Barriers to achieving the health MDGs and how these can be overcome Action for Global Health UK Policy Conference London, 28 June 2010 Isabelle de Zoysa.
International Health Policy Program -Thailand Policy decision on multi drug resistant(MDR), extreme drug resistant(XDR) tuberculosis screening: How it.
NATIONAL TB 2012 INDICATOR ANALYSIS REPORT Presented by: Sandile Ginindza Lugogo Sun Hotel 05 th -7 th June 2013 Ministry of Health NTCP.
1 [INSERT SPEAKER NAME DATE & LOCATION HERE] Ethics of Tuberculosis Prevention, Care and Control MODULE 2: BACKGROUND ON TUBERCULOSIS Insert country/ministry.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
U.S. Global Health Initiative GHI Forum with GBC Lois Quam, Executive Director May 17, 2011.
Philippe Chiliade, MD, MHA Technical Advisor, Clinical Care, FHI 12 August 2008 Family Health International Implementing HIV Care & Treatment Progress.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
World Vision Experiences in Making ART Treatment Affordable and Available Dr. Daniel J Malleboyina M.B.B.S, MBA, MPH Regional Advisor HIV & AIDS- Asia.
Global Fund Grant Proposal Round 11: Tuberculosis Nathan Furukawa Gabriella Boyle Rebekah Miner Paa Kobina Forson Xiaoxue Huang Hunter Pugh Gap Analysis.
THE GLOBAL FUND SUSTAINING THE GAINS AND IMPACT Uganda November 2013.
Global Tuberculosis Control 2007 Did we reach the 2005 targets? Will we achieve the Millennium Development Goals?
Roundtable. Detection and treatment of TB Andrew Black.
Gap Analysis: Tuberculosis Care in Malawi Round 11 proposal to the Global Fund to Fight AIDS, Tuberculosis and Malaria Africa 3: Team Malawi Arianna, Babatunde,
Tuberculosis - the opportunity in our lifetime Dr. Lucica Ditiu | Executive Secretary | Stop TB Partnership 09.April.2013 | Brussels, Belgium.
PMDT IN CHINESE TAIPEI ECONOMY Anita Pei-Chun Chan, MD, PhD Medical Officer, TCDC Associated Director, TB Research Center, TCDC Assistant Professor, Institute.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.
TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA
TB- HIV Collaborative activities in Romania- may 2006 status
Country Progress Report Cambodia
Progress in Implementing collaborative TB/HIV activities
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
TB-HIV Last updated: November 2018.
Knowledge gaps in formulating TB Control Policies for Prisons
Key issues in DOTS implementation
World Tuberculosis Day 2016
Update on Global Fund ATM
Vietnam Investment and Finance for TB
The STOP TB Strategy – 2009 VISION: A TB-free world
A Time of Commitments and Actions to accelerate action to End TB
Presentation transcript:

MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor

Global burden of TB in million incident cases of TB 1.3 million people died from the disease –940,000 deaths among people who were HIV-negative –320,000 among people who were HIV-positive –170,000 death from MDR-TB 410,000 women died from TB (250,000 among HIV-negative women and 160,000 among HIV- positive women, an estimated numbers). 74,000 TB deaths among HIV- negative children 2

What is MDR-TB? Multi-drug resistant tuberculosis (MDR-TB) is a form of TB, when Mycobacteria is resistant to main anti-TB drugs: –Isoniazid and Rifampicin MDR-TB is treated with at least 4 medications, but usually 5-7 drugs Duration of MDR-TB is between 18 – 24 months Patient is getting injections for 6-8 months and oral meds daily, under the direct observation $10,000 – is a minimum cost for 1 case of MDR-TB patient –It’s about $250 to treat sensitive TB 3 A MDR/XDR-TB patient in the Philippines receives trea A MDR TB patient in the Philippines receives treatment A MDR TB patient in the Philippines receives treatment

Percentage of new TB cases with MDR-TB 4 Data: WHO Global TB report 2013

Percentage of previously treated TB cases with MDR-TB 5 Data: WHO Global TB report 2013

Trends in MDR-TB estimation and notification 6

7 Do we know how many prevalent MDR-TB cases in the world?

Gaps in MDR-TB detection 8

Gaps in DR-TB detection Proportion of DST coverage among new cases 2.0%4.0% 5.1% (3.9% in HBC) Proportion of DST coverage among previously treated cases 4.7%6.0% 8.7% (7.7% in HBC) Prevalence of MDR-TB among new cases 3.1%3.7%3.6% Prevalence of MDR-TB among retreatment cases 19.0%20.0%20.2% 9 WHO target is 20% WHO target is 100%

Why are we behind? Countries need to have strong labs to diagnose MDR-TB; however GeneXpert is helping is to screen patients; Countries need to have facilities, staff and drugs to enroll patients on treatment; Programs need to keep patients adherent to a very long and unpleasant treatment…; 10 Photos: William Wells

Treatment outcomes for patients diagnosed with MDR-TB. 2007–2010 cohorts. 11 Data: WHO Global TB report 2013

Treatment outcomes for patients diagnosed with MDR-TB. 2007–2010 cohorts. By Regions 12 Data: WHO Global TB report 2013

Monitoring time trends in % of MDR in new TB cases Data: WHO report

What is USAID doing to control MDR-TB? USAID has a target to support diagnosis and treatment of 57,200 MDR-TB cases/year USAID provides technical assistance to high burden countries to develop National Response Plans USAID helps national TB Programs to detect TB cases through laboratory support and GeneXpert procurement USAID supports country programs to improve quality of care provided USAID helps counties to leverage donor funds for TB and MDR-TB through assistance and collaboration 14

What should the international community do to stop MDR-TB epidemic? Have bold and inspiring VISION to eliminate TB and MDR-TB Focus on achieving results through partnership and collaboration Be accountable for progress made and resources used Include children, women and vulnerable populations in every TB program Build sustainable systems and promote countries ownership Be ambitious! 15

Next Session Room Numbers: Please fill out an evaluation by going to this session’s page on your mobile app OR by filling out a paper evaluation in the back of the room. Thank you! Integration of Family Planning Services into MNCH Programming in Liberia301 The Realities of Integration: NCDs and TB in Ethiopia (Continued)302 Integrating Family Planning with Obstetric Fistula Services: Achieving Reproductive Intentions307 Operational Research Training in the 21st Century308 Constant Contact: Reinforcing Provider Training with Mobile Messages and Supervision in Ghana (Continued)310 Indoor Residual Spraying: A Weapon in the Fight Against Malaria311 Increasing District Level, Evidence-Based Decision Making in Cote d'Ivoire405 Making Every Life Count: Strengthening Civil Registration-Vital Statistics Systems407 How Strengthening Medicines Regulatory Authorities Can Increase Access to Medicines (Continued)413 Child TB: No More Crying, No More Dying?414 Creating the Next Condom: TPPs for Next Generation MPTsBetts Theatre Sustainable Health Gain from Smart Governance of Hospitals and Health Systems Continental Ballroom Gender, Medicines, and the Road to Equity #AreWeThereYet? Grand Ballroom